Abstract:Abstract Cervical cancer, one of the most common causes of cancer-related death among women in the world, has been linked to the presence of a particular oncoprotein that is predominantly transferred through sexual contact with an infected host. In 90% of cervical cancer deaths, a correlation has been found with the expression of the viral genome of HPV16 E6. As a result, HPV16 E6 has emerged as an optimistic therapeutic drug target for the treatment of cervical cancer. In order to develop a drug that is capable of disturbing the genome expression activity of HPV16 E6, it is imperative to identify the key chemical features of its known inhibitors. In this study, we present an investigationon identifying potential inhibitors of HPV16 E6 by utilizing pharmacophore-based virtual screening, molecular docking, ADME prediction, and molecular dynamics simulation. In the initial stage, we generated a ligand-based pharmacophore model based on the features of four known HPV16 E6 inhibitors (CA24, CA25, CA26, and CA27)via the PHASE module implanted in the Schrödinger suite. We constructedfour-point pharmacophore features, which consists of three hydrogen bond acceptors (A) and one aromatic ring (R). The common pharmacophore features further employed as a query for virtual screening against the ASINEX database via the Schrödinger suite. The pharmacophore-based virtual screening filtered out top 2000 hits, based on the fitness score. We applied the molecular docking studies for further compound filtration using Glide which provide three ligand filtering phases, namely HTVS, SP, XP. Initially, 1000 compounds were obtained from HTVS docking. Based on the glide score, they were further filtered to 500 hits by employing docking in standard precision mode. Finally, the best four hits were identified using docking in XP mode. The four compounds were then further subjected to ADME profile prediction by engaging the Qikprop module. The ADME properties of the four fell within a satisfactory range and the compounds exhibited anticipated pharmacokinetic properties. These compounds were further investigated to determine the binding stability of the protein-ligand complex at a different time scale (100 ns) by using the desmond package for a molecular dynamics simulation. These molecular dynamics simulation studies revealed that theCYS 51 and GLN 107 proteins are residues of HPV 16 E6 binding sites, and the root mean square deviation (RMSD) and root mean square fluctuations (RMSF) values for these residues were also found to be within satisfactory ranges and suggest a crucial role in enhancing the stability of the protein-ligand complex during the simulation. From these computational investigations, we concluded that the four potential compounds are appropriate for further study, and potential clinical investigation, as HPV16 E6 inhibitors.

Efficient Inhibition of Human Papillomavirus 16 L1 Pentamer Formation by a Carboxylatopillarene and a P-Sulfonatocalixarene

The Inhibitory Properties of Acidic Functionalised Calix[4]arenes on Human Papillomavirus Pentamer Formation

Enantioselective Inhibition of Human Papillomavirus L1 Pentamer Formation by Chiral‐Proline Modified Calix[4]arenes: Targeting the Protein Interface

Peptidic Inhibitors for in Vitro Pentamer Formation of Human Papillomavirus Capsid Protein L1.

Pharmacophore based virtual screening for identification of effective inhibitors to compact HPV 16 E6 a triggered cervical cancer

Identification of HPV16 in suspected cases of cervical lesions and docking Study of its L1 protein with some natural inhibitors.

Discovery of reactive peptide inhibitors of human papillomavirus oncoprotein E6

Human papillomavirus-16 E6-positive cervical cancer attenuated by potent 2-(4-biphenylyl)-N-(1-ethyl-4-piperidinyl) acetamide second-generation analogs with improved binding affinity

Design of Selective PARP-1 Inhibitors and Antitumor Studies

Novel computational and drug design strategies for inhibition of human papillomavirus-associated cervical cancer and DNA polymerase theta receptor by Apigenin derivatives

In silico screening and molecular dynamics simulations toward new human papillomavirus 16 type inhibitors

In silico Study of Natural inhibitors for Human papillomavirus-18 E6 protein

Discovery of 2-(2-aminobenzo[d]thiazol-6-yl) Benzo[d]oxazol-5-amine Derivatives That Regulated HPV Relevant Cellular Pathway and Prevented Cervical Cancer from Abnormal Proliferation.

Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway.

25‐hydroxycholesterol inhibits human papillomavirus infection in cervical epithelial cells by perturbing cytoskeletal remodeling

Molecular Docking and Molecular Dynamics Simulation-Based Identification of Natural Inhibitors against Druggable Human Papilloma Virus Type 16 Target

The inhibitory effects and mechanisms of polymannuroguluronate sulfate against human papillomavirus infection in vitro and in vivo

Antiproliferative and Pro-Apoptotic Effects of a Phenolic-Rich Extract from Lycium barbarum Fruits on Human Papillomavirus (HPV) 16-Positive Head Cancer Cell Lines

C-71980262, a novel small molecule against human papilloma virus-16 E6 (HPV-16 E6) with anticancer potency against cervical cancer: A computational guided in vitro approach

A Novel Human Papillomavirus 16 L1 Pentamer-Loaded Hybrid Particles Vaccine System: Influence of Size on Immune Responses.

Construction and Property Investigation of Serial Pillar[5]arene-Based [1]Rotaxanes